Veto cells could make stem cell transplants safer for blood cancer patients
NCT ID NCT03622788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow failure. Participants receive chemotherapy and radiation before the transplant, followed by the veto cells. The goal is to find a safe dose and see if patients are alive and engrafted 42 days later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cytokine-treated veto cells (donor immune cells)
- What this could lead to
- If it works, this could make stem cell transplants safer and more effective for people with blood cancers by reducing the risk of graft-versus-host disease.
- What could go wrong
- This is a very early, small trial (16 people) focused on finding the right dose and checking safety. It may not work as hoped, and there are risks like severe graft-versus-host disease or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?